, Volume 40, Issue 11, pp 1278–1285

Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

  • R. G. Thompson
  • L. Pearson
  • O. G. Kolterman

DOI: 10.1007/s001250050821

Cite this article as:
Thompson, R.G., Pearson, L. & Kolterman, O.G. Diabetologia (1997) 40: 1278. doi:10.1007/s001250050821


The effects of 4 weeks’ administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial. Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 µg four times per day (breakfast, lunch, dinner, and evening snack), 30 µg three times per day (breakfast, lunch and dinner [BLD]), 30 µg three times per day (breakfast, dinner and evening snack [BDS]), and 60 µg twice per day (breakfast and dinner). After 4 weeks of pramlintide 30 µg four times per day administration, there was a statistically significant reduction in the mean 24 h plasma glucose concentration when compared to placebo (- 1.4 ± 0.5 vs 0.3 ± 0.5 µmol/1, p = 0.009). Serum fructosamine concentrations were reduced 62 ± 10 µmol/1 in the pramlintide 30 mg four times per day group, 43 ± 7 µmol/l in the pramlintide 30 µg three times per day (BLD) group, 47 ± 6 µmol/1 in the pramlintide 30 µg three times per day (BDS) group, 46 ± 7 µmol/1 in the pramlintide 60 µg twice per day group, and 29 ± 8 µmol/1 by placebo. The incidence of hypoglycaemia was not different in any pramlintide group compared to the placebo group. Nausea, the most frequent adverse event, subsided after the first week of treatment in the majority of patients. In conclusion, pramlintide improved blood glucose control over a 4-week period without increased hypoglycaemia and was well tolerated. Future studies using a longer period of pramlintide administration with assessment of HbA1c as the measurement of glycaemic control are warranted.


Pramlintide amylin serum fructosamine plasma glucose HbA1c IDDM 



area under the plasma concentration curve


maximum plasma concentration


minimum plasma concentration


not statistically significant


not applicable


breakfast, lunch and dinner


breakfast, dinner and evening snack


hemoglobin Alc

Download to read the full article text

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • R. G. Thompson
    • 1
  • L. Pearson
    • 1
  • O. G. Kolterman
    • 1
  1. 1.Amylin Pharmaceuticals Inc.San DiegoUSA

Personalised recommendations